Evidence Hub

Tolerance induction for EGFR TKI hypersensitivity in lung cancer: Case report and review

Haraguchi Hashiguchi M, Adachi T, Asaoka M, Ito T, Kaburagi S, Kagyo J, Okata-Karigane U, Takahashi C et al.

The journal of allergy and clinical immunology. Global, 2026

Abstract

This report highlights the successful use of oral desensitization to manage delayed-type hypersensitivity to afatinib, enabling continuation of treatment for epidermal growth factor receptor-mutated non-small cell lung cancer. In the absence of standardized protocols, it offers valuable insights for managing similar clinical challenges.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free